INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses In Excess of $250,000 to Contact the FirmAccesswire • 06/10/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the FirmAccesswire • 06/09/23
INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the FirmAccesswire • 06/08/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the FirmBusiness Wire • 06/07/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 06/07/23
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based TherapiesBusiness Wire • 06/06/23
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and EducationBusiness Wire • 06/01/23
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire • 04/26/23
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023Business Wire • 04/14/23
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research ProgramBusiness Wire • 03/16/23